Nanobiotix's promising data from Phase I/II head and neck cancer trial presented at ASCO - Nanotechnology News (press release)

Nanobiotix's promising data from Phase I/II head and neck cancer trial presented at ASCO Nanotechnology News (press release) NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, presented the results of the Phase I/II head and neck cancer trial with its lead product candidate, ...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2s0PNZE
via IFTTT